Osaka-based drugmaker Shionogi & Co. said its experimental COVID-19 vaccine was found safe and effective in a study, potentially creating an indigenous supply source for the nation as it races to complete a booster drive in hopes of curbing future outbreaks.
The recombinant protein-based vaccine that was being tested as a booster shot met its primary endpoint in the Phase 2/3 trials, Shionogi said in a statement Friday announcing the interim report’s findings. There were no serious treatment-related adverse events, deaths or adverse events of special interest, it said.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
We humbly apologize for the inconvenience.